Suppr超能文献

参与抗抑郁药和精神运动兴奋剂选择性抑制的儿茶酚胺转运体嵌合体的结构域。

Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants.

作者信息

Buck K J, Amara S G

机构信息

Howard Hughes Medical Institute, Oregon Health Sciences University, Portland 97201, USA.

出版信息

Mol Pharmacol. 1995 Dec;48(6):1030-7.

PMID:8848002
Abstract

Reuptake systems for monoamines are the initial sites of action for a wide range of therapeutic antidepressants and drugs of abuse, such as cocaine. To delineate structural domains of the dopamine and norepinephrine transporters that contribute to differential interaction with reuptake inhibitors with antidepressant or reinforcing properties, a series of recombinant transporter chimeras were generated and transiently expressed in HeLa cells. The inhibition constants (Ki values) for cocaine and a variety of selective transport inhibitors were determined for each chimera. Analyses of functional chimeras delineate a segment spanning transmembrane domains 5-7 of the norepinephrine transporter of primary importance for high affinity binding of tricyclic and nontricyclic antidepressants (e.g., Ki < 20nM desipramine or nisoxetine). In contrast, all chimeras containing dopamine transporter sequences from this region resemble the dopamine transporter, which demonstrates higher affinity for psychomotor stimulants compared with antidepressants (e.g., Ki = 391 +/- 39 nM cocaine compared with 9365 +/- 1260 nM desipramine). A region including transmembrane domains 1-3 of the norepinephrine transporter also contributes to the interaction of desipramine and nisoxetine, whereas the analogous region of the dopamine transporter influences the affinity for piperazine derivatives (e.g., GBR12909 and LR1111) that are selective for the dopamine transporter. These analyses provide a framework for identifying the precise structural determinants of monoamine transporters involved in selective interactions with antidepressant and psychomotor stimulant reuptake inhibitors.

摘要

单胺再摄取系统是多种治疗性抗抑郁药和滥用药物(如可卡因)的初始作用位点。为了描绘多巴胺和去甲肾上腺素转运体的结构域,这些结构域有助于与具有抗抑郁或强化特性的再摄取抑制剂产生不同的相互作用,我们构建了一系列重组转运体嵌合体,并在HeLa细胞中瞬时表达。测定了每种嵌合体对可卡因和多种选择性转运抑制剂的抑制常数(Ki值)。对功能性嵌合体的分析描绘了去甲肾上腺素转运体跨膜结构域5 - 7的一段区域,这对于三环和非三环抗抑郁药的高亲和力结合至关重要(例如,地昔帕明或尼索西汀的Ki < 20nM)。相比之下,该区域包含多巴胺转运体序列的所有嵌合体都类似于多巴胺转运体,与抗抑郁药相比,它对精神运动兴奋剂具有更高的亲和力(例如,可卡因的Ki = 391 +/- 39 nM,而去甲肾上腺素的Ki = 9365 +/- 1260 nM)。去甲肾上腺素转运体包括跨膜结构域1 - 3的区域也有助于地昔帕明和尼索西汀的相互作用,而多巴胺转运体的类似区域则影响对多巴胺转运体具有选择性的哌嗪衍生物(例如,GBR12909和LR1111)的亲和力。这些分析为确定单胺转运体与抗抑郁药和精神运动兴奋剂再摄取抑制剂选择性相互作用中涉及的精确结构决定因素提供了一个框架。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验